down arrow

Harbin Gloria Pharmaceuticals Co., Ltd.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000QG8
  • SHE: 002437
CNY
3.50
-0.14 (-3.85%)

Sep 24

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Harbin Gloria Pharmaceuticals Co., Ltd.

Why is Harbin Gloria Pharmaceuticals Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 5.00%
  • The company has been able to generate a Return on Capital Employed (avg) of 5.00% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -7.76% and Operating profit at 27.93% over the last 5 years
3
Flat results in Mar 26
  • INTEREST(HY) At CNY 1.6 MM has Grown at 31.01%
  • OPERATING CASH FLOW(Y) Lowest at CNY 283.88 MM
  • NET SALES(HY) At CNY 1,009.56 MM has Grown at -11.01%
4
With ROE of 15.80%, it has a attractive valuation with a 2.35 Price to Book Value
  • Over the past year, while the stock has generated a return of NA, its profits have risen by 52.6% ; the PEG ratio of the company is 0.2
5
Underperformed the market in the last 1 year
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Harbin Gloria Pharmaceuticals Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harbin Gloria Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Harbin Gloria Pharmaceuticals Co., Ltd.
9.03%
1.47
40.71%
China Shanghai Composite
0.9%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-7.76%
EBIT Growth (5y)
27.93%
EBIT to Interest (avg)
22.82
Debt to EBITDA (avg)
0.25
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.09
Tax Ratio
9.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.24%
ROE (avg)
4.75%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.30
EV to EBIT
19.27
EV to EBITDA
14.96
EV to Capital Employed
3.12
EV to Sales
2.15
PEG Ratio
0.24
Dividend Yield
NA
ROCE (Latest)
16.18%
ROE (Latest)
15.80%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
ROCE(HY)

Highest at 17.77%

DEBT-EQUITY RATIO (HY)

Lowest at -36.92 %

RAW MATERIAL COST(Y)

Fallen by -3.63% (YoY

NET PROFIT(9M)

Higher at CNY 295.89 MM

OPERATING PROFIT MARGIN(Q)

Highest at 21.48 %

PRE-TAX PROFIT(Q)

Highest at CNY 89.7 MM

-5What is not working for the Company
NET SALES(Q)

Lowest at CNY 467.96 MM

EPS(Q)

Lowest at CNY 0.03

Here's what is working for Harbin Gloria Pharmaceuticals Co., Ltd.

Debt-Equity Ratio
Lowest at -36.92 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Profit
At CNY 295.89 MM has Grown at 61.44%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Operating Profit Margin
Highest at 21.48 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at CNY 89.7 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Higher at CNY 295.89 MM
than preceding 12 month period ended Jun 2026
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost
Fallen by -3.63% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Harbin Gloria Pharmaceuticals Co., Ltd.

Net Sales
Lowest at CNY 467.96 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Net Sales
At CNY 467.96 MM has Fallen at -11.84%
over average net sales of the previous four periods of CNY 530.83 MM
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

EPS
Lowest at CNY 0.03
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Footer loading